Meta AnalysisID 8032
玻璃体腔内贝伐珠单抗联合曲安奈德对比贝伐珠单抗单药治疗糖尿病性黄斑水肿的比较：系统评价和Meta分析
CRD42023408843
Comparison of Intravitreal Bevacizumab Combined with Triamcinolone and Bevacizumab Alone in Treatment of Diabetic Macular Edema: A Systematic Review and Meta-Analysis
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 8032
- Evidence Id
- 16590
- Core Evidence Id
- 16590
- Source Meta Analysis Id
- 8032
- Herb2 Meta Analysis Id
- HBMA008032
- Crd Id
- CRD42023408843
- Title
- Comparison of Intravitreal Bevacizumab Combined with Triamcinolone and Bevacizumab Alone in Treatment of Diabetic Macular Edema: A Systematic Review and Meta-Analysis
- Review Question
- Comparison of Intravitreal Bevacizumab Combined with Triamcinolone and Bevacizumab Alone in Treatment of Diabetic Macular Edema: A Systematic Review and Meta-Analysis
- Study Type Included
- Patients with type 1 or type 2 diabetes who had secondary DME diagnosed by fluorescein fundus angiography and 3D- optical coherence tomography. Exclusion criteria:The patient had eye diseases besides DME, such as vitreous hemorrhage and neovascular glaucoma. The patient had a history of intravitreal injections of bevacizumab or glucocorticoids within the last three months. The patient had eye surgery performed within three months. Follow-up time is less than six weeks. The research type is a non-RCT or review, animal experiment, etc. The level of literature is poor, and the data of literature is incomplete.
- Condition Being Studied
- Diabetic macular edema is the major cause of vision loss due to diabetic retinopathy.DME pathogenesis includes genetic transmission, increased production of free radicals, advanced glycosylation end products, inflammatory factors, and vascular endothelial growth factors. Interventions: The patients in the experimental group received triamcinolone treatment along with an bevacizumab medication, whereas the patients in the control group received only an bevacizumab medication.
- Participant
- Patients with type 1 or type 2 diabetes who had secondary DME diagnosed by fluorescein fundus angiography and 3D- optical coherence tomography. Exclusion criteria:The patient had eye diseases besides DME, such as vitreous hemorrhage and neovascular glaucoma. The patient had a history of intravitreal injections of bevacizumab or glucocorticoids within the last three months. The patient had eye surgery performed within three months. Follow-up time is less than six weeks. The research type is a non-RCT or review, animal experiment, etc. The level of literature is poor, and the data of literature is incomplete.
- Animal
- Human Disease Modelled
- Intervention
- The patients in the experimental group received triamcinolone treatment along with an bevacizumab medication,
- Comparator Control
- The patients in the control group received only an bevacizumab medication.
- Main Outcome
- Best corrected visual acuity degree, central macular thickness, number of injections, and incidence of adverse effect after treatment.
- Outcome Measure
- Additional Outcome
- Cataract, lens opacity and transient anterior chamber reactions.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Bevacizumab; Diabetes Mellitus; Diabetic Retinopathy; Edema; Humans; Macular Edema; Triamcinolone
- Contact
- Yuyang Miao [email protected]
- Organisational Affiliation
- Changchun University of Chinese Medicine
- Funding Source
- Jilin Province Health, Wellness, Science and Technology Capacity Improvement Project. The funder number of this project is 2021LC054 and this project was funded since 2021. Grant number(s) State the funder, grant or award number and the date of award Jilin Province Science and Technology Development Plan Project. The funder number of this project is 20210506026ZP and this project was funded since 2021.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-04-26
- Registration Date
- 2023-05-07
- Anticipated Start Date
- 2023-02-01
- Anticipated Completion Date
- 2023-05-31
- Title Cn
- 玻璃体腔内贝伐珠单抗联合曲安奈德对比贝伐珠单抗单药治疗糖尿病性黄斑水肿的比较：系统评价和Meta分析
- Title En
- Comparison of Intravitreal Bevacizumab Combined with Triamcinolone and Bevacizumab Alone in Treatment of Diabetic Macular Edema: A Systematic Review and Meta-Analysis
- Bilingual Status
- complete